Last reviewed · How we verify
Herombopag + CsA
Herombopag + CsA is a Thrombopoietin receptor agonist + Calcineurin inhibitor Small molecule drug developed by Peking Union Medical College Hospital. It is currently FDA-approved for Immune thrombocytopenia (ITP). Also known as: control.
Herombopag is a thrombopoietin receptor agonist that stimulates platelet production, combined with cyclosporine A (CsA), an immunosuppressant that inhibits T-cell activation.
Herombopag is a thrombopoietin receptor agonist that stimulates platelet production, combined with cyclosporine A (CsA), an immunosuppressant that inhibits T-cell activation. Used for Immune thrombocytopenia (ITP).
At a glance
| Generic name | Herombopag + CsA |
|---|---|
| Also known as | control |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Thrombopoietin receptor agonist + Calcineurin inhibitor |
| Target | TPO receptor (c-Mpl) + Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Herombopag works by binding to and activating the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells, thereby increasing platelet production. Cyclosporine A is added to suppress immune-mediated platelet destruction by inhibiting calcineurin-dependent T-cell activation. This combination approach addresses both the production and immune destruction pathways in thrombocytopenia.
Approved indications
- Immune thrombocytopenia (ITP)
Common side effects
- Thrombosis
- Renal impairment
- Hypertension
- Infection
- Headache
Key clinical trials
- Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (PHASE2)
- Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia (PHASE2)
- Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia (PHASE2)
- Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System (PHASE4)
- A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herombopag + CsA CI brief — competitive landscape report
- Herombopag + CsA updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI
Frequently asked questions about Herombopag + CsA
What is Herombopag + CsA?
How does Herombopag + CsA work?
What is Herombopag + CsA used for?
Who makes Herombopag + CsA?
Is Herombopag + CsA also known as anything else?
What drug class is Herombopag + CsA in?
What development phase is Herombopag + CsA in?
What are the side effects of Herombopag + CsA?
What does Herombopag + CsA target?
Related
- Drug class: All Thrombopoietin receptor agonist + Calcineurin inhibitor drugs
- Target: All drugs targeting TPO receptor (c-Mpl) + Calcineurin
- Manufacturer: Peking Union Medical College Hospital — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Immune thrombocytopenia (ITP)
- Also known as: control
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing